Compare Mesoblast Limited (MESO) vs Annaly Capital Management, Inc. (NLY) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Mesoblast Limited vs Annaly Capital Management, Inc. — how do they compare? Mesoblast Limited trades at $16.36 (market cap $2.17B), while Annaly Capital Management, Inc. trades at $22.67 (market cap $16.63B). The key difference: Annaly Capital Management, Inc. is far larger — about 7.7× Mesoblast Limited's market cap, and Annaly Capital Management, Inc. pays a 13.22% dividend while Mesoblast Limited pays none. Which is the better fit depends on your goals.
| MESO | NLY | |
|---|---|---|
Market Cap | $2.17B | $16.63B |
Sector | Technology | Financials |
52-Week High | $20.96 | $24.40 |
52-Week Low | $12.88 | $19.96 |
Enterprise Value | $2.17B | — |
Dividend Yield | — | 13.22% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
MESO trades at $16.63, down 3.98% on the day, with a bullish technical outlook supported by moving averages. The company shows strong revenue growth with Ryoncil generating $115 million in annual revenue, though it remains unprofitable with a net loss of $102 million. Recent developments include positive Phase 3 trial progress and FDA BLA filings for new treatments.
Investment outlook balances promising pipeline progress against significant financial losses. The stock offers growth potential through commercial expansion but carries substantial risk from continued cash burn and regulatory hurdles. Analyst consensus leans bullish with 45% buy ratings, reflecting optimism about the company's transition to commercial-stage operations.
NLY trades at $22.73, down 1.22% today, with a bullish technical signal and strong earnings beat history. The stock shows a low P/E of 7.42 and a 13% dividend yield, supported by recent analyst upgrades. Revenue grew to $2.24B in 2025, with net income margin at 91.17%, though cash flow from operations declined to $693M. The consensus price target is $24.80, implying 9% upside.
Outlook remains positive given earnings momentum and high yield, but risks include interest rate sensitivity and elevated debt-to-asset ratio of 23.55. Institutional sentiment is bullish with 57% buy ratings, though macroeconomic shifts could pressure mortgage REIT performance.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Mesoblast Limited
Mesoblast Limited is a global leader in allogeneic cellular medicines. The company develops innovative, commercially-ready mesenchymal lineage cell (MLC) technology for the treatment of various inflammatory and cardiovascular conditions. Their pipeline focuses on leveraging the anti-inflammatory, tissue repair, and immune-modulating properties of these cells for diseases with high unmet medical needs, such as acute graft versus host disease (aGVHD) and chronic heart failure.
Read more on MESO →About Annaly Capital Management, Inc.
Annaly Capital Management Inc is an American mortgage real estate investment trust. The company segments its operations into Residential and Commercial real estate investments. While Annaly's Residential assets are primarily comprised of agency mortgage-backed securities and debentures, it is primarily invested in commercial mortgage loans and mortgage-backed securities in its Commercial unit through its subsidiary, Annaly Commercial Real Estate Group. Agency mortgage-backed securities and debentures make up the majority of the company's overall portfolio. Most of the company's counterparties are located in the U.S. Annaly generates nearly all of its revenue from the spread between interest earned on its assets and interest payments made on its borrowings.
Read more on NLY →
